Notably, therapeutic inhibition of IL-17 has been shown to reverse both the molecular signatures and clinical symptoms of psoriasis in most patients, firmly positioning IL-17 and IL-17–producing T cells as core components of the current disease model. The gene discussed is IL17A; the disease is psoriasis.